What Happened
- Meghalaya's Health Minister W Shylla has stated that the state has the highest HIV caseload in India, with 10,293 people living with HIV currently receiving antiretroviral therapy (ART) — the largest such treatment cohort relative to population among all Indian states.
- Disease burden over the past decade: 749 deaths linked to HIV, with East Khasi Hills district accounting for 435 deaths, followed by West Jaintia Hills (123) and East Jaintia Hills (90).
- NACO has sanctioned ₹17.8 crore to the Meghalaya AIDS Control Society for 2025–26 for awareness programmes, targeted outreach, opioid substitution therapy centres, expanded screening, and care support services.
- The state government has separately approved a ₹25-crore five-year mission-mode programme to expand testing, treatment, and awareness at the community level.
- The Northeast India region has historically had disproportionately high HIV prevalence, linked to intravenous drug use (IDU) along trafficking routes, migration patterns, and limited healthcare access — factors that create a concentrated epidemic profile distinct from India's general population epidemic.
Static Topic Bridges
National AIDS Control Programme (NACP) and Institutional Framework
The National AIDS Control Programme (NACP) is India's flagship programme for HIV/AIDS prevention and control, administered by the National AIDS Control Organisation (NACO) under the Ministry of Health and Family Welfare. NACP has progressed through five phases since 1992:
- Phase I (1992–1999): Blood safety and awareness
- Phase II (1999–2006): Direct interventions and state capacity building
- Phase III (2007–2012): Scale-up and district-level decentralisation
- Phase IV (2012–2017): Consolidation and enhanced government funding
- Phase V (2021–2026): Target — ending AIDS as a public health threat by 2030 per UN SDG 3.3
State AIDS Control Societies (SACS) implement the programme at the state level, receiving funds from NACO. The programme follows a "Test and Treat" policy (adopted April 2017): all HIV-positive persons are eligible for ART regardless of CD4 count.
- NACP Phase I launched: 1992; currently in Phase V (2021–2026)
- Implementing body: NACO, Ministry of Health and Family Welfare
- State implementing bodies: State AIDS Control Societies (SACS) — e.g., Meghalaya AIDS Control Society
- "Test and Treat" policy: universal ART eligibility since April 2017
- NACP Phase V goal: end AIDS epidemic as public health threat by 2030 (SDG 3.3)
- NACO funding to Meghalaya SACS (2025–26): ₹17.8 crore
Connection to this news: Meghalaya's disproportionate HIV caseload represents a concentrated epidemic — driven by IDU and high-risk behaviours — requiring targeted NACP interventions (opioid substitution therapy, needle exchange) beyond the general awareness and ART provision that serve the broader Indian epidemic.
HIV and AIDS (Prevention and Control) Act, 2017
The HIV and AIDS (Prevention and Control) Act, 2017 is India's first dedicated legislation protecting the rights of persons living with HIV and those affected by HIV. It came into force on September 10, 2018. The Act prohibits discrimination against HIV-positive persons in employment, healthcare, public services, and educational institutions. It mandates informed consent for HIV testing, protects confidentiality of HIV status, and provides for courts to adjudicate complaints of discrimination. The Act also criminalises the transmission of HIV through deliberate acts. It represents a shift from a purely public health approach to a rights-based legal framework for HIV management.
- Act name: The HIV and AIDS (Prevention and Control) Act, 2017
- In force: September 10, 2018
- Key provisions: anti-discrimination in employment/healthcare/education, informed consent for testing, confidentiality protection
- Redress mechanism: Ombudsman to hear complaints of discrimination; court jurisdiction for violations
- Significance: first statutory rights framework for PLHIV (Persons Living with HIV) in India
Connection to this news: Meghalaya's high HIV burden makes the enforcement of the 2017 Act particularly critical in the state — ensuring that the 10,293+ people on ART can access treatment, employment, and social services without discrimination or stigma, which is crucial for treatment adherence and epidemic control.
Concentrated Epidemic vs. Generalised Epidemic: Northeast India's HIV Profile
HIV epidemics are categorised by UNAIDS as concentrated (prevalence >5% in high-risk groups but <1% in general population) or generalised (prevalence >1% in general population). Northeast India — including Meghalaya, Manipur, Mizoram, and Nagaland — has a concentrated epidemic driven primarily by intravenous drug use (IDU) linked to the Golden Triangle drug trafficking route (Myanmar-Thailand-Laos border region). This is distinct from South India's generalised epidemic, which is driven by heterosexual transmission. The IDU-driven concentrated epidemic requires a different set of interventions: harm reduction (needle exchange, opioid substitution therapy) over conventional awareness campaigns.
- UNAIDS epidemic types: concentrated (>5% in high-risk groups) vs. generalised (>1% in general population)
- Northeast India profile: concentrated epidemic, IDU-driven, linked to Golden Triangle drug routes
- South India profile: generalised epidemic, primarily heterosexual transmission
- Key intervention for IDU-driven epidemic: opioid substitution therapy (OST), needle/syringe exchange programmes
- NACO's targeted intervention programme (TIP): designed for high-risk groups including IDU populations
- Districts with highest burden in Meghalaya: East Khasi Hills (435 deaths), West Jaintia Hills (123), East Jaintia Hills (90)
Connection to this news: Meghalaya's ₹25-crore state programme includes opioid substitution therapy centres — directly addressing the IDU transmission vector — suggesting that state authorities recognise the concentrated epidemic nature of their crisis and are deploying the appropriate harm-reduction toolkit.
Key Facts & Data
- Meghalaya HIV treatment caseload: 10,293 persons on ART (highest in India per Health Minister)
- HIV-related deaths in Meghalaya (past decade): 749; East Khasi Hills: 435, West Jaintia Hills: 123, East Jaintia Hills: 90
- NACO funding to Meghalaya AIDS Control Society (2025–26): ₹17.8 crore
- State government programme: ₹25 crore, 5-year mission-mode HIV response
- Statement by: Health Minister W Shylla
- NACP Phase V duration: 2021–2026; goal: end AIDS as public health threat by 2030
- HIV and AIDS (Prevention and Control) Act, 2017: in force September 10, 2018
- Northeast India epidemic type: concentrated, IDU-driven (linked to Golden Triangle)